Opinion

Video

Recent Insights Into Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Panelists comment on recent updates from the International Myeloma Society/ American Society of Hematology (IMS/ASH) 2024 annual meetings, discussing the efficacy of approved bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM), including teclistamab (MajesTEC-1), elranatamab (MagnetisMM-3), and talquetamab (MonumenTAL-1).

Video content above is prompted by the following:

  • Briefly comment on recent updates from IMS/ASH 2024. In terms of efficacy, how do these approved bispecific antibodies perform?
  • MajesTEC-1, Teclistamab in R/R MM
  • MagnetisMM-3, Elranatamab in R/R MM
  • MonumenTAL-1, Talquetamab in R/R MM

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Video

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Apr 8th 2025 - May 14th 2025

online-activity
View More
Related Content
María-Victoria Mateos, MD, PhD, consultant physician, Hematology Department, associate professor, medicine, University of Salamanca
April 18th 2025

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple Myeloma | Image Credit: © LASZLO – stock.adobe.com
April 14th 2025

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Cilta-Cel in Multiple Myeloma | Image Credit: © Corona Borealis – stock.adobe.com
April 12th 2025

Cilta-Cel Yields QOL Benefits and Prolonged Treatment-Free Intervals vs SOC in R/R Myeloma

Smoldering Myeloma | Image Credit: © LASZLO – stock.adobe.com
April 11th 2025

Daratumumab Significantly Reduces Progression Risk in High-Risk Smoldering Multiple Myeloma